Genes alter GLP‑1 outcomes

Glucagon-like peptide 1 is a gut hormone your body releases after you eat, and it tells the brain and pancreas that food has arrived. Drugs such as semaglutide copy that signal, which is why they can lower appetite and help people lose weight. (nature.com) The signal works by docking onto a receptor, which is a protein on a cell that acts like a lock waiting for the right key. The glucagon-like peptide 1 receptor is that lock, and semaglutide is one of the keys designed to press it harder and for longer than the natural hormone does. (nature.com) A second hormone called glucose-dependent insulinotropic polypeptide also talks to the same appetite-and-metabolism system after meals. Tirzepatide is unusual because it pushes both the glucagon-like peptide 1 receptor and the glucose-dependent insulinotropic polypeptide receptor at the same time. (nature.com) That helps explain why two people can take the same drug and get very different results. A Nature study published on April 8, 2026 looked at almost 28,000 people and found average weight loss of 11.7% over about 8.3 months, but the spread was huge, from little or no loss to roughly 30%. (nature.com) The new result is that some of that spread tracks back to ordinary DNA differences in the drug targets themselves. The study linked common variants in the genes called GLP1R and GIPR to both weight-loss response and the risk of nausea or vomiting on these medicines. (nature.com) One glucagon-like peptide 1 receptor variant was tied to less weight loss on glucagon-like peptide 1 drugs. A separate glucose-dependent insulinotropic polypeptide receptor variant was tied to nausea and vomiting specifically in people taking tirzepatide, which hits that second receptor directly. (nature.com) The logic is straightforward even if the biology is not. If the lock on the cell is shaped a little differently because of inherited DNA, the same drug key may not turn it with the same force in every person. (nature.com) The researchers did not build a ready-to-use prescription test from this. Nature’s accompanying analysis said the variants are clues, not a full explanation, because food environment, dose, adherence, other biology, and many more genes still shape what happens on the scale and in the stomach. (nature.com) What the paper did show is that combining several genetic signals improved the ability to sort people into groups with higher or lower odds of strong weight loss or side effects. That is the kind of result drug developers use to design better trials years before doctors use it in routine care. (nature.com) The finding is already spilling outside genetics labs because companies are trying to build the next wave of obesity treatments around fullness, protein intake, and muscle preservation. Scientific American reported that researchers and food companies are using these receptor clues to think about which patients may need different diet support or different follow-on drugs rather than a one-size-fits-all plan. (scientificamerican.com) So the story is not that a cheek swab can now tell you whether semaglutide or tirzepatide will work. The story is that the first big human data set has shown, in the actual drug targets, that inherited differences help decide who loses more weight and who feels sicker getting there. (nature.com)